Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 22, 2020

Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints

Antisense Therapeutics is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.

Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints